Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BlackBerry Limited (BB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BlackBerry Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while BlackBerry Limited trades at $10.78 (market cap $6.42B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.2× BlackBerry Limited's market cap, and BlackBerry Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BB | |
|---|---|---|
Market Cap | $39.89B | $6.42B |
Sector | Health | Technology |
52-Week High | $491.22 | $12.81 |
52-Week Low | $278.09 | $3.15 |
Enterprise Value | $38.15B | $6.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BlackBerry (BB) trades at $10.97, down 4.02% today, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights strong QNX growth in automotive and robotics sectors, though valuation metrics remain elevated with P/E at 109.7 and P/S at 11.26.
The outlook is cautiously optimistic as BlackBerry's turnaround gains traction with improved cash flow and QNX momentum. Key risks include execution challenges amid rich valuation and competitive pressures. Analyst consensus leans neutral with 85.7% hold ratings and $10.50 price target, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →
